{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464378222
| IUPAC_name = 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3''H''-1,4-benzodiazepine-2-thione
| image = Quazepam.svg
| width = 199
| image2 = Quazepam ball-and-stick model.png
| width2 = 180

<!--Clinical data-->
| tradename = Doral
| Drugs.com = {{drugs.com|CDI|quazepam}}
| MedlinePlus = a684001
| pregnancy_AU = D
| pregnancy_US = X
| legal_CA = Schedule IV
| legal_US = Schedule IV
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 29–35%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 39 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| IUPHAR_ligand = 7288
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 36735-22-5
| ATC_prefix = N05
| ATC_suffix = CD10
| PubChem = 4999
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01589
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4825
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JF8V0828ZI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00457
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200472

<!--Chemical data-->
| C=17 | H=11 | Cl=1 | F=4 | N=2 | S=1
| molecular_weight = 386.795 g/mol
| smiles = FC(F)(F)CN1C(=S)C/N=C(\c2cc(Cl)ccc12)c3ccccc3F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IKMPWMZBZSAONZ-UHFFFAOYSA-N
}}

'''Quazepam''' (marketed under brand names '''Doral''', '''Dormalin''') is a relatively long-acting [[benzodiazepine]] derivative drug developed by the Schering Corporation in the 1970s.<ref>US Patent 3845039</ref> Quazepam is indicated for the treatment of insomnia including sleep induction and sleep maintenance.<ref>{{cite journal |author=Mendels J |title=Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients |journal=J Clin Psychiatry |volume=55 |issue=2 |pages=60–5 |date=February 1994 |pmid=7915708 |doi= |url=}}</ref> Quazepam induces impairment of motor function and has relatively (and uniquely) selective [[hypnotic]] and [[anticonvulsant]] properties with considerably less overdose potential than other benzodiazepines (due to its novel receptor-subtype selectively).<ref>{{cite journal |author=Yasui M |author2=Kato A |author3=Kanemasa T |author4=Murata S |author5=Nishitomi K |author6=Koike K |author7=Tai N |author8=Shinohara S |author9=Tokomura M |author10=Horiuchi M |author11=Abe K. |title=[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes] |volume=25 |issue=3 |pages=143–51 |date=June 2005 |pmid=16045197 |journal=Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology }}</ref><ref>{{cite journal |vauthors=Ongini E, Parravicini L, Bamonte F, Guzzon V, Iorio LC, Barnett A |title=Pharmacological studies with quazepam, a new benzodiazepine hypnotic |journal=Arzneimittelforschung |volume=32 |issue=11 |pages=1456–62 |year=1982 |pmid=6129857 |doi= |url=}}</ref> Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the [[sleep architecture]].<ref>{{cite journal |vauthors=Roth T, Tietz EI, Kramer M, Kaffeman M |title=The effect of a single dose of quazepam (Sch-16134) on the sleep of chronic insomniacs |journal=J. Int. Med. Res. |volume=7 |issue=6 |pages=583–7 |year=1979 |pmid=42593 |doi= |url=}}</ref> Quazepam is a trifluoroalkyl type of benzodiazepine, like [[fletazepam]], [[halazepam]], [[triflubazam]] and [[triflunordazepam]]. Quazepam is unique amongst benzodiazepines in that it selectively targets the GABA<sub>A</sub> α<sub>1</sub> subunit receptors which are responsible for inducing sleep. Its mechanism of action is very similar to [[zolpidem]] and [[zaleplon]] in its pharmacology and can successfully substitute for zolpidem and zaleplon in animal studies.<ref>{{cite journal |vauthors=Rowlett JK, Spealman RD, Lelas S, Cook JM, Yin W |title=Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABA(A)/alpha1 receptors |journal=Psychopharmacology |volume=165 |issue=3 |pages=209–15 |date=January 2003 |pmid=12420154 |doi=10.1007/s00213-002-1275-z |url=http://www.springerlink.com/content/392vkmeej4at9yuy/fulltext.pdf |format=PDF}}</ref><ref>{{cite journal |vauthors=Iorio LC, Barnett A, Billard W |title=Selective affinity of 1-N-trifluoroethyl benzodiazepines for cerebellar type 1 receptor sites |journal=Life Sci. |volume=35 |issue=1 |pages=105–13 |date=July 1984 |pmid=6738302 |doi= 10.1016/0024-3205(84)90157-7|url=}}</ref><ref>{{cite journal |vauthors=Yezuita JP, McCabe RT, Barnett A, Iorio LC, Wamsley JK |title=Use of the selective benzodiazepine-1 (BZ-1) ligand [3H]2-oxo-quazepam (SCH 15-725) to localize BZ-1 receptors in the rat brain |journal=Neurosci. Lett. |volume=88 |issue=1 |pages=86–92 |date=May 1988 |pmid=2899863 |doi= 10.1016/0304-3940(88)90320-5|url=}}</ref>

==Indications==
Quazepam is used for short-term treatment of [[insomnia]] related to sleep induction or sleep maintenance problems and has demonstrated superiority over other benzodiazepines such as [[temazepam]]. It had a fewer incidence of side effects than temazepam, including less sedation, amnesia, and less motor-impairment.<ref>{{cite journal |author=Tsoi WF |title=Insomnia: drug treatment |journal=Ann. Acad. Med. Singap. |volume=20 |issue=2 |pages=269–72 |date=March 1991 |pmid=1679317 |doi= |url=}}</ref><ref name="Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby JA, Kales JD 1986 345–52">{{cite journal |vauthors=Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby JA, Kales JD |title=Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal |journal=Clin. Pharmacol. Ther. |volume=39 |issue=3 |pages=345–52 |date=March 1986 |pmid=2868823 |doi= 10.1038/clpt.1986.51|url=}}</ref><ref>{{cite journal |vauthors=Hernández Lara R, Del Rosal PL, Ponce MC |title=Short-term study of quazepam 15 milligrams in the treatment of insomnia |journal=J. Int. Med. Res. |volume=11 |issue=3 |pages=162–6 |year=1983 |pmid=6347748 |doi= |url=}}</ref><ref>{{cite journal |author=Caldwell JR |title=Short-term quazepam treatment of insomnia in geriatric patients |journal=Pharmatherapeutica |volume=3 |issue=4 |pages=278–82 |year=1982 |pmid=6128741 |doi= |url=}}</ref> Usual dosage is 7.5 to 15&nbsp;mg orally at bedtime.<ref>{{cite journal |vauthors=Kales A, Scharf MB, Bixler EO, Schweitzer PK, Jacoby JA, Soldatos CR |title=Dose-response studies of quazepam |journal=Clin. Pharmacol. Ther. |volume=30 |issue=2 |pages=194–200 |date=August 1981 |pmid=6113910 |doi= 10.1038/clpt.1981.148|url=}}</ref>

Quazepam is effective as a [[premedication]] prior to surgery.<ref>{{cite journal |vauthors=Nishiyama T, Yamashita K, Yokoyama T, Imoto A, Manabe M |title=Effects of quazepam as a preoperative night hypnotic: comparison with brotizolam |journal=J Anesth |volume=21 |issue=1 |pages=7–12 |year=2007 |pmid=17285406 |doi=10.1007/s00540-006-0445-2 |url=http://www.springerlink.com/content/n18j6x4n0570v711/fulltext.pdf?page=1 |format=PDF}}</ref>

==Side effects==
Quazepam has fewer side effects than other benzodiazepines and less potential to induce [[drug tolerance|tolerance]] and [[rebound effects]].<ref>{{cite journal |vauthors=Barnett A, Iorio LC, Ongini E |title=The sedative-hypnotic properties of quazepam, a new hypnotic agent |journal=Arzneimittelforschung |volume=32 |issue=11 |pages=1452–6 |year=1982 |pmid=6129856 |doi= |url=}}</ref><ref>{{cite journal |author=Lader M |title=Rebound insomnia and newer hypnotics |journal=Psychopharmacology |volume=108 |issue=3 |pages=248–55 |year=1992 |pmid=1523276 |doi= 10.1007/BF02245108|url=}}</ref> There is significantly less potential for quazepam to induce [[respiratory depression]] or to adversely affect motor coordination than other [[benzodiazepines]].<ref>{{cite journal |vauthors=Murray A, Bellville JW, Comer W, Danielson L |title=Respiratory effects of quazepam and pentobarbital |journal=J Clin Pharmacol |volume=27 |issue=4 |pages=310–3 |date=April 1987 |pmid=2890670 |doi= 10.1002/j.1552-4604.1987.tb03020.x|url=}}</ref> The different side effect profile of quazepam may be due to its more selective binding profile to type 1 benzodiazepine receptors.<ref>{{cite journal |vauthors=Billard W, Crosby G, Iorio L, Chipkin R, Barnett A |title=Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand |journal=Life Sci. |volume=42 |issue=2 |pages=179–87 |year=1988 |pmid=2892106 |doi= 10.1016/0024-3205(88)90681-9|url=}}</ref><ref>{{cite journal |vauthors=Wamsley JK, Hunt MA |title=Relative affinity of quazepam for type-1 benzodiazepine receptors in brain |journal=J Clin Psychiatry |volume=Suppl |issue= |pages=15–20 |series=52 |date=September 1991 |pmid=1680119 |doi= |url=}}</ref>
*[[Ataxia]]<ref>{{cite journal |vauthors=Martinez HT, Serna CT |title=Short-term treatment with quazepam of insomnia in geriatric patients |journal=Clin Ther |volume=5 |issue=2 |pages=174–8 |year=1982 |pmid=6130842 |doi= |url=}}</ref>
*Daytime [[somnolence]]<ref>{{cite journal |vauthors=Mendels J, Stern S |title=Evaluation of the short-term treatment of insomnia in out-patients with 15 milligrams of quazepam |journal=J. Int. Med. Res. |volume=11 |issue=3 |pages=155–61 |year=1983 |pmid=6347747 |doi= |url=}}</ref>
*[[Hypokinesia]]<ref>{{cite journal |vauthors=Aden GC, Thatcher C |title=Quazepam in the short-term treatment of insomnia in outpatients |journal=J Clin Psychiatry |volume=44 |issue=12 |pages=454–6 |date=December 1983 |pmid=6361006 |doi= |url=}}</ref>
*[[Cognitive]] and performance impairments<ref>{{cite journal |vauthors=Schaffler K, Kauert G, Wauschkuhn CH, Klausnitzer W |title=Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam |journal=Arzneimittelforschung |volume=39 |issue=2 |pages=276–83 |date=February 1989 |pmid=2567171 |doi= |url=}}</ref>

==Tolerance and dependence==
Tolerance may occur to quazepam but more slowly than seen with other benzodiazepines such as [[triazolam]].<ref>{{cite journal  |vauthors=Saletu B, Anderer P, Brandstätter N, etal |title=Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam) |journal=Neuropsychobiology |volume=29 |issue=2 |pages=69–90 |year=1994 |pmid=8170529 |doi= 10.1159/000119067|url=}}</ref> However, quazepam causes significantly less [[drug tolerance]] and less withdrawal symptoms including less [[rebound insomnia]] upon discontinuation compared to other benzodiazepines.<ref>{{cite journal |vauthors=Chung M, Hilbert JM, Gural RP, Radwanski E, Symchowicz S, Zampaglione N |title=Multiple-dose quazepam kinetics |journal=Clin. Pharmacol. Ther. |volume=35 |issue=4 |pages=520–4 |date=April 1984 |pmid=6705450 |doi= 10.1038/clpt.1984.70|url=}}</ref><ref>{{cite journal |vauthors=Mamelak M, Csima A, Price V |title=A comparative 25-night sleep laboratory study on the effects of quazepam and triazolam on chronic insomniacs |journal=J Clin Pharmacol |volume=24 |issue=2-3 |pages=65–75 |year=1984 |pmid=6143767 |doi= 10.1002/j.1552-4604.1984.tb02767.x|url=http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=6143767}}</ref><ref>{{cite journal |vauthors=Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Niklaus DE, Manfredi RL |title=Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam |journal=Clin. Pharmacol. Ther. |volume=40 |issue=4 |pages=378–86 |date=October 1986 |pmid=3530586 |doi= 10.1038/clpt.1986.194|url=}}</ref><ref>{{cite journal  |vauthors=Altamura AC, Colacurcio F, Mauri MC, etal |title=[Controlled clinical study on the effect of quazepam versus triazolam in patients with sleep disorders] |language=Italian |journal=Minerva Psichiatr |volume=30 |issue=3 |pages=159–64 |year=1989 |pmid=2691808 |doi= |url=}}</ref> Quazepam may cause less [[rebound effects]] than other type1 benzodiazepine receptor selective [[nonbenzodiazepine]] drugs due to its longer half-life.<ref name="Yamadera H 1998 515–20">{{cite journal |author=Yamadera H |title=[Recent progress in development of hypnotic drugs] |language=Japanese |journal=Nippon Rinsho |volume=56 |issue=2 |pages=515–20 |date=February 1998 |pmid=9503861 |doi= |url=}}</ref> Short-acting hypnotics often cause next day [[rebound anxiety]]. Quazepam due to its pharmacological profile does not cause next day [[rebound withdrawal effects]] during treatment.<ref>{{cite journal |vauthors=Hilbert JM, Battista D |title=Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics |journal=J Clin Psychiatry |volume=Suppl |issue= |pages=21–6 |series=52 |date=September 1991 |pmid=1680120 |doi= |url=}}</ref>

No firm conclusions can be drawn, however, whether long-term use of quazepam does not produce tolerance as few, if any, long-term clinical trials extending beyond 4 weeks of chronic use have been conducted.<ref name="pmid2894293" /> Quazepam should be withdrawn gradually if used beyond 4 weeks of use to avoid the risk of a severe [[benzodiazepine withdrawal syndrome]] developing. Very high dosage administration over prolonged periods of time, up to 52 weeks, of quazepam in animal studies provoked severe withdrawal symptoms upon abrupt discontinuation, including excitability, [[hyperactivity]], [[convulsions]] and the death of two of the monkeys due to withdrawal-related convulsions. More monkeys died however, in the diazepam-treated monkeys.<ref>{{cite journal  |vauthors=Black HE, Szot RJ, Arthaud LE, etal |title=Preclinical safety evaluation of the benzodiazepine quazepam |journal=Arzneimittelforschung |volume=37 |issue=8 |pages=906–13 |date=August 1987 |pmid=2890357 |doi= |url=}}</ref> In addition it has now been documented in the medical literature that one of the major metabolites of quazepam, ''N''-desalkyl-2-oxoquazepam ([[N-Desalkylflurazepam|''N''-desalkylflurazepam]]), which is long-acting and prone to accumulation, binds unselectively to benzodiazepine receptors, thus quazepam may not differ all that much pharmacologically from other benzodiazepines.<ref>{{cite journal |vauthors=Nikaido AM, Ellinwood EH |title=Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance |journal=Psychopharmacology |volume=92 |issue=4 |pages=459–64 |year=1987 |pmid=2888152 |doi= 10.1007/bf00176478|url=}}</ref>

==Special precautions==
Benzodiazepines require special precaution if used in the during pregnancy, in children, alcohol or drug-dependent individuals and individuals with [[comorbid]] [[psychiatric disorders]].<ref>{{Cite journal | last1 = Authier | first1 = N. | last2 = Balayssac | first2 = D. | last3 = Sautereau | first3 = M. | last4 = Zangarelli | first4 = A. | last5 = Courty | first5 = P. | last6 = Somogyi | first6 = AA. | last7 = Vennat | first7 = B. | last8 = Llorca | first8 = PM. | last9 = Eschalier | first9 = A.  | title = Benzodiazepine dependence: focus on withdrawal syndrome. | journal = Ann Pharm Fr | volume = 67 | issue = 6 | pages = 408–13 |date=Nov 2009 | doi = 10.1016/j.pharma.2009.07.001 | pmid = 19900604 }}</ref>

Quazepam and its [[active metabolites]] are excreted into [[breast milk]].<ref>{{cite journal |vauthors=Hilbert JM, Gural RP, Symchowicz S, Zampaglione N |title=Excretion of quazepam into human breast milk |journal=J Clin Pharmacol |volume=24 |issue=10 |pages=457–62 |date=October 1984 |pmid=6150944 |doi= 10.1002/j.1552-4604.1984.tb01819.x|url=http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=6150944}}</ref>

Accumulation of one of the [[active metabolite]]s of quazepam, [[N-Desalkylflurazepam|''N''-desalkylflurazepam]], may occur in the elderly. A lower dose may be required in the elderly.<ref>{{cite journal |vauthors=Hilbert JM, Chung M, Radwanski E, Gural R, Symchowicz S, Zampaglione N |title=Quazepam kinetics in the elderly |journal=Clin. Pharmacol. Ther. |volume=36 |issue=4 |pages=566–9 |date=October 1984 |pmid=6478742 |doi= 10.1038/clpt.1984.220|url=}}</ref>

==Elderly==
Quazepam is more tolerable for elderly patients compared to [[flurazepam]] due to its reduced next day impairments.<ref>{{cite journal |author=Dement WC |title=Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency Test |journal=J Clin Psychiatry |volume=Suppl |issue= |pages=31–7 |series=52 |date=September 1991 |pmid=1680123 |doi= |url=}}</ref> However, another study showed marked next day impairments after repeated administration due to accumulation of quazepam and its long-acting metabolites. Thus the medical literature shows conflicts on quazepam's side effect profile.<ref>{{cite journal  |vauthors=Takahashi T, Okajima Y, Otsubo T, etal |title=Comparison of hangover effects among triazolam, flunitrazepam and quazepam in healthy subjects: a preliminary report |journal=Psychiatry Clin. Neurosci. |volume=57 |issue=3 |pages=303–9 |date=June 2003 |pmid=12753571 |doi= 10.1046/j.1440-1819.2003.01121.x|url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1323-1316&date=2003&volume=57&issue=3&spage=303}}</ref> A further study showed significant balance impairments combined with an unstable posture after administration of quazepam in test subjects.<ref>{{cite journal |vauthors=Nakamura M, Ishii M, Niwa Y, Yamazaki M, Ito H |title=[Studies of time-course changes in human body balance after ingestion of long-acting hypnotics] |language=Japanese |journal=Nippon Jibiinkoka Gakkai Kaiho |volume=107 |issue=2 |pages=145–51 |date=February 2004 |pmid=15032004 |doi= 10.3950/jibiinkoka.107.145|url=}}</ref>
An extensive review of the medical literature regarding the management of insomnia and the elderly found that there is considerable evidence of the effectiveness and durability of non-drug treatments for insomnia in adults of all ages and that these interventions are underutilized. Compared with the benzodiazepines including quazepam, the [[nonbenzodiazepine]] sedative/hypnotics appeared to offer few, if any, significant clinical advantages in efficacy or tolerability in elderly persons. It was found that newer agents with novel mechanisms of action and improved safety profiles, such as the melatonin agonists, hold promise for the management of chronic insomnia in elderly people. Long-term use of sedative/hypnotics for insomnia lacks an evidence base and has traditionally been discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment ([[anterograde amnesia]]), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of these agents remain to be determined. It was concluded that more research is needed to evaluate the long-term effects of treatment and the most appropriate management strategy for elderly persons with chronic insomnia.<ref>{{cite journal | journal = Am J Geriatr Pharmacother |date=June 2006 | volume = 4 | issue = 2 | pages = 168–92 | title = Management of chronic insomnia in elderly persons | author = Bain KT | pmid = 16860264 | doi = 10.1016/j.amjopharm.2006.06.006}}</ref>

==Pharmacology==
Quazepam is selective for type I benzodiazepine receptors containing the α<sub>1</sub> subunit, similar to other drugs such as [[zaleplon]] and [[zolpidem]]. As a result, quazepam has little or no [[muscle relaxant]] properties. Most other benzodiazepines are unselective and bind to type1 GABA<sub>A</sub> receptors and type2 GABA<sub>A</sub> receptors. Type1 GABA<sub>A</sub> receptors include the α<sub>1</sub> subunit containing GABA<sub>A</sub> receptors which are responsible for [[hypnotic]] properties of the drug. Type 2 receptors include the α<sub>2</sub>, α<sub>3</sub> and α<sub>5</sub> subunits which are responsible for [[anxiolytic]] action, [[amnesia]] and muscle relaxant properties.<ref>{{cite journal |vauthors=Tanaka M, Suemaru K, Watanabe S, Cui R, Li B, Araki H |title=Comparison of short- and long-acting benzodiazepine-receptor agonists with different receptor selectivity on motor coordination and muscle relaxation following thiopental-induced anesthesia in mice |journal=J. Pharmacol. Sci. |volume=107 |issue=3 |pages=277–84 |date=July 2008 |pmid=18603831 |doi= 10.1254/jphs.FP0071991|url=http://www.jstage.jst.go.jp/article/jphs/107/3/277/_pdf |format=PDF}}</ref><ref>{{cite journal |vauthors=Giorgi O, Corda MG, Gritti I, Mariotti M, Ongini E, Biggio G |title=Binding sites for [3H]2-oxo-quazepam in the brain of the cat: evidence for heterogeneity of benzodiazepine recognition sites |journal=Neuropharmacology |volume=28 |issue=7 |pages=715–8 |date=July 1989 |pmid=2569691 |doi= 10.1016/0028-3908(89)90156-1|url=}}</ref> Thus quazepam may have less side effects than other benzodiazepines but, it has a very long half-life of 25 hours which reduces its benefits as a [[hypnotic]] due to likely next day sedation. It also has two active metabolites with half-lives of 28 and 79 hours. Quazepam may also cause less [[drug tolerance]] than other benzodiazepines such as [[temazepam]] and [[triazolam]] perhaps due to its subtype selectivity.<ref>{{cite journal |vauthors=Jochemsen R, Breimer DD |title=Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles |journal=Curr Med Res Opin |volume=Suppl 4 |issue= |pages=60–79 |series=8 |year=1984 |pmid=6144464 |doi=10.1185/03007998409109545 |url=}}</ref><ref>{{cite journal |author=Kales A |title=Quazepam: hypnotic efficacy and side effects |journal=Pharmacotherapy |volume=10 |issue=1 |pages=1–10; discussion 10–2 |year=1990 |pmid=1969151 |doi= 10.1002/j.1875-9114.1990.tb02545.x}}</ref><ref>{{cite journal |vauthors=Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD |title=Quazepam and flurazepam: long-term use and extended withdrawal |journal=Clin. Pharmacol. Ther. |volume=32 |issue=6 |pages=781–8 |date=December 1982 |pmid=7140142 |doi= 10.1038/clpt.1982.236|url=}}</ref><ref>{{cite journal |vauthors=Hilbert JM, Chung M, Maier G, Gural R, Symchowicz S, Zampaglione N |title=Effect of sleep on quazepam kinetics |journal=Clin. Pharmacol. Ther. |volume=36 |issue=1 |pages=99–104 |date=July 1984 |pmid=6734056 |doi= 10.1038/clpt.1984.146|url=}}</ref> The longer half-life of quazepam may have the advantage however, of causing less [[rebound insomnia]] than shorter acting subtype selective [[nonbenzodiazepines]].<ref name="Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby JA, Kales JD 1986 345–52"/><ref name="Yamadera H 1998 515–20"/> However, one of the major metabolites of quazepam, the ''N''-desmethyl-2-oxoquazepam (aka ''N''-desalkylflurazepam), binds unselectively to both type1 and type2 GABA<sub>A</sub> receptors. The ''N''-desmethyl-2-oxoquazepam metabolite also has a very long half-life and likely contributes to the pharmacological effects of quazepam.<ref>{{cite journal |vauthors=Wang JS, DeVane CL |title=Pharmacokinetics and drug interactions of the sedative hypnotics |journal=Psychopharmacol Bull |volume=37 |issue=1 |pages=10–29 |year=2003 |pmid=14561946 |doi= 10.1007/BF01990373|url=http://www.medworksmedia.com/psychopharmbulletin/pdf/12/010-029_PB%20W03_Wang_final.pdf |format=PDF}}</ref>

==Pharmacokinetics==
[[File:2-Oxoquazepam.svg|thumb|left|upright=0.68|alt=2-Oxoquazepam, a major active quazepam metabolite|2-Oxoquazepam, a major active quazepam metabolite.]]
Quazepam has an absorption half-life of 0.4 hours with a peak in plasma levels after 1.75 hours. It is eliminated both renally and through feces.<ref>{{cite journal |vauthors=Zampaglione N, Hilbert JM, Ning J, Chung M, Gural R, Symchowicz S |title=Disposition and metabolic fate of 14C-quazepam in man |journal=Drug Metab. Dispos. |volume=13 |issue=1 |pages=25–9 |year=1985 |pmid=2858372 |doi= |url=}}</ref> The active metabolites of quazepam are 2-oxoquazepam and ''N''-desalkyl-2-oxoquazepam. The ''N''-desalkyl-2-oxoquazepam metabolite has only limited pharmacological activity compared to the parent compound quazepam and the active metabolite 2-oxoquazepam. Quazepam and its major active metabolite 2-oxoquazepam both show high selectivity for the type1 GABA<sub>A</sub> receptors.<ref>{{cite journal  |vauthors=Corda MG, Sanna E, Concas A, etal |title=Enhancement of gamma-aminobutyric acid binding by quazepam, a benzodiazepine derivative with preferential affinity for type I benzodiazepine receptors |journal=J. Neurochem. |volume=47 |issue=2 |pages=370–4 |date=August 1986 |pmid=3016172 |doi= 10.1111/j.1471-4159.1986.tb04511.x|url=}}</ref><ref>{{cite journal |vauthors=Hilbert JM, Iorio L, Moritzen V, Barnett A, Symchowicz S, Zampaglione N |title=Relationships of brain and plasma levels of quazepam, flurazepam, and their metabolites with pharmacological activity in mice |journal=Life Sci. |volume=39 |issue=2 |pages=161–8 |date=July 1986 |pmid=3724367 |doi= 10.1016/0024-3205(86)90451-0|url=}}</ref><ref>{{cite journal |vauthors=Corda MG, Giorgi O, Longoni B, Ongini E, Montaldo S, Biggio G |title=Preferential affinity of 3H-2-oxo-quazepam for type I benzodiazepine recognition sites in the human brain |journal=Life Sci. |volume=42 |issue=2 |pages=189–97 |year=1988 |pmid=2892107 |doi= 10.1016/0024-3205(88)90682-0|url=}}</ref><ref>{{cite journal |vauthors=Miller LG, Galpern WR, Byrnes JJ, Greenblatt DJ |title=Benzodiazepine receptor binding of benzodiazepine hypnotics: receptor and ligand specificity |journal=Pharmacol. Biochem. Behav. |volume=43 |issue=2 |pages=413–6 |date=October 1992 |pmid=1359574 |doi= 10.1016/0091-3057(92)90170-K|url=http://linkinghub.elsevier.com/retrieve/pii/0091-3057(92)90170-K}}</ref> The [[elimination half-life]] range of quazepam is between 27 and 41 hours.<ref name="pmid2894293">{{cite journal |vauthors=Ankier SI, Goa KL |title=Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia |journal=Drugs |volume=35 |issue=1 |pages=42–62 |date=January 1988 |pmid=2894293 |doi= 10.2165/00003495-198835010-00003|url=}}</ref>

==Interactions==
The absorption rate is likely to be significantly reduced if quazepam is taken in the fasted state reducing the [[hypnotic]] effect of quazepam. If 3 or more hours have passed since eating food then some food should be eaten before taking quazepam.<ref>{{cite journal |vauthors=Yasui-Furukori N, Takahata T, Kondo T, Mihara K, Kaneko S, Tateishi T |title=Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam |journal=Br J Clin Pharmacol |volume=55 |issue=4 |pages=382–8 |date=April 2003 |pmid=12680887 |pmc=1884227 |doi= 10.1046/j.1365-2125.2003.01775.x|url=http://www3.interscience.wiley.com/cgi-bin/fulltext/118882427/PDFSTART |format=PDF}}</ref><ref>{{cite journal  |vauthors=Kim Y, Morikawa M, Ohsawa H, etal |title=Effects of foods on the pharmacokinetics and clinical efficacy of quazepam |journal=Nihon Shinkei Seishin Yakurigaku Zasshi |volume=23 |issue=5 |pages=205–10 |date=October 2003 |pmid=14653226 |doi= |url=}}</ref>

==Mechanism of action==
Quazepam modulates specific GABA<sub>A</sub> receptors via the [[GABAA receptor|benzodiazepine site]] on the GABA<sub>A</sub> receptor. This modulation enhances the actions of GABA, causing an increase in opening frequency of the chloride ion channel which results in an increased influx of chloride ions into the GABA<sub>A</sub> receptors. Quazepam, unique amongst benzodiazepine drugs selectively targets type1 benzodiazepine receptors which results reduced [[sleep latency]] in promotion of sleep.<ref>{{cite journal |vauthors=Meldrum BS, Chapman AG |title=Benzodiazepine receptors and their relationship to the treatment of epilepsy |journal=Epilepsia |volume=Suppl 1 |issue= |pages=S3–13 |series=27 |year=1986 |pmid=3017690 |doi= 10.1111/j.1528-1157.1986.tb05731.x}}</ref><ref>{{cite journal  |vauthors=Corda MG, Giorgi O, Longoni BM, etal |title=Characterization of 3H-2-oxo-quazepam binding in the human brain |journal=Prog. Neuropsychopharmacol. Biol. Psychiatry |volume=12 |issue=5 |pages=701–12 |year=1988 |pmid=2906158 |doi= 10.1016/0278-5846(88)90015-2|url=}}</ref><ref>{{cite journal |vauthors=Roth TG, Roehrs TA, Koshorek GL, Greenblatt DJ, Rosenthal LD |title=Hypnotic effects of low doses of quazepam in older insomniacs |journal=J Clin Psychopharmacol |volume=17 |issue=5 |pages=401–6 |date=October 1997 |pmid=9315991 |doi= 10.1097/00004714-199710000-00009|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0271-0749&volume=17&issue=5&spage=401}}</ref> Quazepam also has some [[anticonvulsant]] properties.<ref>{{cite journal |vauthors=Chapman AG, De Sarro GB, Premachandra M, Meldrum BS |title=Bidirectional effects of beta-carbolines in reflex epilepsy |journal=Brain Res. Bull. |volume=19 |issue=3 |pages=337–46 |date=September 1987 |pmid=3119161 |doi= 10.1016/0361-9230(87)90102-X|url=http://linkinghub.elsevier.com/retrieve/pii/0361-9230(87)90102-X}}</ref>

==EEG and sleep==
Quazepam has potent [[Sleep induction|sleep inducing]] and sleep maintaining properties.<ref>{{cite journal |vauthors=Mauri MC, Gianetti S, Pugnetti L, Altamura AC |title=Quazepam versus triazolam in patients with sleep disorders: a double-blind study |journal=Int J Clin Pharmacol Res |volume=13 |issue=3 |pages=173–7 |year=1993 |pmid=7901174 |doi= |url=}}</ref><ref>{{cite journal |author=Wettstein JG |title=Effects of the novel benzodiazepine agonist quazepam on suppressed behavior of monkeys |journal=Eur. J. Pharmacol. |volume=155 |issue=1-2 |pages=19–25 |date=October 1988 |pmid=2907488 |doi= 10.1016/0014-2999(88)90398-6|url=http://linkinghub.elsevier.com/retrieve/pii/0014-2999(88)90398-6}}</ref> Studies in both animals and humans have demonstrated that EEG changes induced by quazepam resemble normal sleep patterns whereas other benzodiazepines disrupt normal sleep. Quazepam promotes [[slow wave sleep]].<ref>{{cite journal |vauthors=Mariotti M, Ongini E |title=Differential effects of benzodiazepines on EEG activity and hypnogenic mechanisms of the brain stem in cats |journal=Arch Int Pharmacodyn Ther |volume=264 |issue=2 |pages=203–19 |date=August 1983 |pmid=6139096 |doi= |url=}}</ref><ref>{{cite journal |vauthors=Kawasaki H, Urabe M, Nuki C, Yamamoto R, Takasaki K, Ohno H |title=[Electroencephalographic study of Sch 161 (quazepam), a new benzodiazepine hypnotic, in rats and rabbits] |language=Japanese |journal=Nippon Yakurigaku Zasshi |volume=90 |issue=4 |pages=221–38 |date=October 1987 |pmid=3428780 |doi= 10.1254/fpj.90.221|url=}}</ref> This positive effect of quazepam on [[sleep architecture]] may be due to its high selectivity for type1 benzodiazepine receptors as demonstrated in animal and human studies. This makes quazepam unique in the [[benzodiazepine]] family of drugs.<ref>{{cite journal |author=Sieghart W |title=Several new benzodiazepines selectively interact with a benzodiazepine receptor subtype |journal=Neurosci. Lett. |volume=38 |issue=1 |pages=73–8 |date=July 1983 |pmid=6136944 |doi= 10.1016/0304-3940(83)90113-1|url=http://linkinghub.elsevier.com/retrieve/pii/0304-3940(83)90113-1}}</ref><ref>{{cite journal |vauthors=Wamsley JK, Golden JS, Yamamura HI, Barnett A |title=Quazepam, a sedative-hypnotic selective for the benzodiazepine type 1 receptor: autoradiographic localization in rat and human brain |journal=Clin Neuropharmacol |volume=Suppl 1 |issue= |pages=S26–40 |series=8 |year=1985 |pmid=2874881 |doi= |url=}}</ref>

==Drug misuse==
{{See also|Benzodiazepine drug misuse}}
Quazepam is a drug with the potential for misuse. Two types of drug misuse can occur either recreational misuse is where the drug is taken to achieve a high or when the drug is continued long term against medical advice.<ref>{{cite journal |vauthors=Griffiths RR, Johnson MW |title=Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds |journal=J Clin Psychiatry |volume=Suppl 9 |issue= |pages=31–41 |series=66 |year=2005 |pmid=16336040 |doi= |url=}}</ref>

==See also==
*[[Benzodiazepine]]
*[[Benzodiazepine dependence]]
*[[Benzodiazepine withdrawal syndrome]]
*[[Long-term effects of benzodiazepines]]

==References==
{{reflist|30em}}

==External links==
* [http://www.inchem.org/documents/pims/pharm/pim932.htm Inchem.org - Quazepam]

{{Benzodiazepines}}
{{Hypnotics and sedatives}}
{{GABAAR PAMs}}

[[Category:Benzodiazepines]]
[[Category:Sedatives]]
[[Category:Hypnotics]]
[[Category:Anticonvulsants]]
[[Category:Muscle relaxants]]
[[Category:Chloroarenes]]
[[Category:Fluoroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Thioamides]]
[[Category:Trifluoromethyl compounds]]